Reply to: “Comment on “Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort””
Saved in:
| Main Authors: | Jisoo Lee, Jae-Young Kim, Jeong-Ju Yoo, Hye Won Lee, Sang Gyune Kim, Young Seok Kim |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | JHEP Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555925000485 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current perspectives on the pharmacological treatment of advanced
hepatocellular carcinoma: a narrative review
by: Hye-Jin Yoo, et al.
Published: (2024-10-01) -
Atezolizumab-Induced Ulcerative Colitis in Patient with Hepatocellular Carcinoma: Case Report and Literature Review
by: Hyuk Kim, et al.
Published: (2024-08-01) -
Current Trends and Impact of Liver Biopsy on Survival in Hepatocellular Carcinoma: A Korean Multicenter Analysis
by: Seong Joon Chun, et al.
Published: (2025-03-01) -
The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan
by: Elise Chia-Hui Tan, et al.
Published: (2025-03-01) -
An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
by: Derek E. Murrell, et al.
Published: (2025-05-01)